multiple myeloma
Available on Demand
Chimeric antigen receptor engineering is now possible for immune cells other than T cells, including macrophages and invariant natural killer T cells.
| 3 min read
Oncopeptides’ Pepaxto has been approved for patients with triple-class refractory multiple myeloma
Page 1 of 1 - 2 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Overcoming barriers in gene therapy
Advanced gene editing, delivery, and analytical tools are driving better gene therapies.
A multiomic approach to profiling brain tumors
Probing the molecular drivers of brain metastasis reveals novel therapeutic targets.
Enhancing immune cell profiling with digital technologies
Software innovations help researchers decode immune complexity in cancer.
